Opinion|Videos|June 24, 2024
The Pathophysiology of Hidradenitis Suppurativa
Author(s)Iltefat Hamzavi, MD
Iltefat Hamzavi, MD, describes the pathophysiology of hidradenitis suppurativa and associated comorbidities that are commonly seen in patients.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What is the pathophysiology of hidradenitis suppurativa (HS) and are there any risk factors for being affected by this disease?
Advertisement
Related to this article
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
3
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5